You are here

  • Home
  • Archive
  • Volume 1, Issue 1
  • Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study

Share

Article menu

Download PDFPDF

Rheumatoid arthritis
Extended report
Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study

Share this article

Click the icon of the social media platform on which you would like to share this article.

Twitter logo Facebook logo LinkedIn logo

Email this article to a friend

We will not keep your email address; we ask for it so your friend knows the email isn't spam.
Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study
(Your Name) has forwarded a page to you from RMD Open
(Your Name) thought you would like to see this page from the RMD Open web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.